Trial Profile

A phase 1/2 trial of QT-019B in systemic lupus erythematosus

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QT 019B (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions; Therapeutic Use

Most Recent Events

17 Oct 2025 New trial record
18 Aug 2025 According to the Qihan Biotech media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QT-019B. This universal, dual-target CAR-T cell therapy is designed to treat refractorysystemic lupus erythematosus (rSLE), and the clearance enables the initiation of a Phase 1/2 clinical trial in the United States.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com